65,437 trials
Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline in Adult Attention Deficit Hyperactivity Disorder (ADHD) Self-Report Scale (ASRS) Total Score at Week 4 — 52.6; -10.9 Unit on a scale
Lung Cancer · Non Small Cell Lung Cancer
Primary: Progression Free Survival — 75; 97; 103; 98 days
Acute Myelogenous Leukemia · Myelodysplastic Syndromes
Primary: Response Rate of the Combination of Bortezomib and Melphalan in Patients With AML and High-risk MDS. — 5; 2 participants
Genital Endometriosis
Primary: Percentage of Participants Administered Add-back Therapy During a 6-month Course of Leuprorelin Treatment — 46.5; 21.7; 26.9 percentage of participants
Obesity
Primary: 24 Hour Average Plasma Growth Hormone Concentration — 0.4; 1.2; 4.1 ng/mL
Insomnia · Attention Deficit Hyperactivity Disorder
Primary: Overall Incidence of Adverse Events — 212; 138; 10; 4 participants
Diabetes
Primary: Clarke Error Grid Analysis — 83.0; 97.7 Percentage of Results
Pain
Primary: Disposition Kinetics of Morphine and Oxycodone Before and After Cannabis Use — 1.64; -1.11; 0.9; 0.99 Geometric Mean Ratio
Male Hypogonadism
Primary: Time to Target Eugonadal Range — 2.85 hours
Genital Tract Mucosal Immunity · Genital Tract Microflora
Primary: %CD4 Expressing CCR5 HIV Co-receptor in the Cervix and Endometrium — 4.9; 11.7; 7.2 % of T-cells expressing CCR5 — p=0.80
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Maximum-tolerated Dose of Pemetrexed With a Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2) — 500 mg/m2
Cowden's Disease · Hamartoma Syndrome, Multiple
Primary: Biochemical Changes in Benign and Malignant Tumor Tissues as Assessed by Immunohistochemistry.
Fibromyalgia
Primary: Absolute Change From Baseline to Endpoint in Mean Pain — -1.0; -0.8; -1.2; -0.8 units on a scale
Schizophrenia
Primary: Time to Exacerbation of Psychotic Symptoms/Impending Relapse — NA; 209 Days — p=<0.0001
Breast Cancer
Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 28; 31 percentage of patients